Hyperlipidemia and mortality in patients on peritoneal dialysis

BMC Nephrology

Table 4 Association between hyperlipidemia and all-cause mortality using subdistribution hazards model

	Model 1		Model 2		Model 3		Model 4
	HR	95%CI	HR	95%CI	HR	95%CI	HR	95%CI
Over the overall follow-up period
Hyperlipidemia (yes/no)	1.49	1.22 to 1.82	1.14	0.93 to 1.39	1.13	0.92 to 1.38	1.16	0.94 to 1.43
From 48-month follow-up onwards
Hyperlipidemia (yes/no)	2.85	1.90 to 4.26	2.22	1.48 to 3.31	2.12	1.42 to 3.18	2.15	1.42 to 3.25

Model 1, unadjusted; model 2, model 1 plus age, sex, body mass index, systolic BP, diastolic BP, current smoking, current alcohol consumption, 24-hour urine volume, Charlson comorbidity index, diabetes mellitus, hypertension, and a history of CVD; model 3, model 2 plus calcium channel blockers, beta-blockers, ACEI/ARBs, diuretics, statins, and aspirin; model 4, model 3 plus hemoglobin, serum albumin, serum uric acid, eGFR, cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, and hs-CRP.
BP, blood pressure; CVD, cardiovascular disease; ACEI/ARBs, angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; CI, confidence interval

ISSN: 1471-2369